Please assess the completion status of the following clinical trial:

Trial Title: Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. newly diagnosed histologically confirmed BC with breast infiltrating carcinoma of histological grade \> 1 (either operable, or locally advanced or inflammatory) candidate for neoadjuvant chemotherapy~2. HER2-negative tumor, defined according to immunohistochemistry or using fluorescent in-situ hybridization (FISH)~3. ECOG performance status 0 or 1~4. Gender: female~5. Age : \>= 18 years old~6. Negative pregnancy test (females of childbearing potential)~7. Willingness to perform double-barrier-contraception during study and for 6 months post chemotherapy treatment (females of childbearing potential)~8. Signed informed consent~Exclusion Criteria:~1. Metastatic or relapsed disease~2. Major surgery \< 3 weeks prior to enrollment~3. Severe pulmonary obstructive or restrictive disease~4. Uncontrolled inflammatory disease (autoimmune or infectious)~5. Clinically significant cardiac disease (NYHA stadium \> 2)~6. Results of laboratory tests (hematology, chemistry) outside specified limits:~   * WBC ≤ 3 x 109/L~  * ANC \< 1.5 x 109/L~  * Platelets \< 100 x 109/L~  * Hb ≤ 9.0 g/dl (≤ 5.6 mmol/l)~  * PTT/ INR \> 1.5 x ULN~  * AST or ALT \> 2.5 x ULN~  * Alkaline Phosphatase \> 2 x ULN~  * Total Bilirubin \> 1.5 x ULN~7. Pregnancy or nursing status~8. Known positive HIV testing~9. Known hypersensitivity to any component of the EndoTAG-1, paclitaxel or FEC formulations~10. History of malignancy other than breast cancer \< 5 years prior to enrollment, except skin cancer (i.e. basal or squamous cell carcinoma) treated locally~11. History of active or significant neurological disorder or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of central nervous system during the trial~12. Concurrent treatment with other experimental products. Participation in another clinical trial with any investigational product within 30 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EndoTAG-1 (Type: EXPERIMENTAL): Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).